Lucent Vision

Lucent Vision is a biotechnology company that developed a proprietary drug-eluting contact lens platform for sustained ophthalmic medication delivery. The technology utilizes a polymer film integrated into a contact lens to provide controlled, long-term release of drugs, addressing the significant issue of patient non-compliance associated with traditional eye drops. Founded by researchers from Harvard Medical School and Boston Children's Hospital, the company's lead programs focused on delivering treatments for glaucoma and allergic conjunctivitis. Lucent Vision was acquired by Johnson & Johnson Vision, leading to the development and commercialization of the first drug-eluting contact lens, Acuvue Theravision with Ketotifen. This innovation represents a significant shift in ocular therapy by combining vision correction with therapeutic drug delivery.